Acadia Pharmaceuticals (ACAD) Asset Utilization Ratio (2011 - 2026)
Acadia Pharmaceuticals (ACAD) posted quarterly Asset Utilization Ratio of 0.69 for Q1 2026, down 19.53% year-over-year from 0.86 in Q1 2025, and down 6.64% quarter-over-quarter from 0.74 in Q4 2025.
Acadia Pharmaceuticals (ACAD) Asset Utilization Ratio (2011 - 2026) Analysis & Trends
Acadia Pharmaceuticals' Asset Utilization Ratio history runs 16 years deep, the most recent figure standing at 0.69 for Q1 2026.
- In Q1 2026, Asset Utilization Ratio fell 19.53% year-over-year to 0.69; the TTM figure through Mar 2026 stood at 0.69 (down 19.53% YoY), while the FY2025 annual figure was 0.78, down 21.27% from the prior year.
- Asset Utilization Ratio for Q1 2026 stood at 0.69, down from 0.74 in the prior quarter.
- The five-year high for Asset Utilization Ratio was 1.05 in Q4 2023, with the low at 0.69 in Q1 2026.
- The 5-year median for Asset Utilization Ratio is 0.86 (2025), against an average of 0.88.
- The sharpest annual moves came in 2022 and 2026: Asset Utilization Ratio surged 32.27% in 2022, then slipped 19.53% in 2026.
- Acadia Pharmaceuticals' Asset Utilization Ratio stood at 0.87 in 2022, then climbed by 21.01% to 1.05 in 2023, then fell by 15.85% to 0.88 in 2024, then decreased by 16.35% to 0.74 in 2025, then fell by 6.64% to 0.69 in 2026.
- Business Quant data shows ACAD's Asset Utilization Ratio at 0.69 in Q1 2026, 0.74 in Q4 2025, and 0.82 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 0.69 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 186.67 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.13 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 0.90 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 0.54 |
| 10 | Acadia Pharmaceuticals | 4.86 Bn | 3.90 Bn | 279.64 Mn | 0.68 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.68 |
| Mar 31, 2026 | 0.69 |
| Dec 31, 2025 | 0.74 |
| Sep 30, 2025 | 0.82 |
| Jun 30, 2025 | 0.86 |
| Mar 31, 2025 | 0.86 |
| Dec 31, 2024 | 0.88 |
| Sep 30, 2024 | 0.98 |
| Jun 30, 2024 | 1.01 |
| Mar 31, 2024 | 1.01 |
| Dec 31, 2023 | 1.05 |
| Sep 30, 2023 | 0.99 |
| Jun 30, 2023 | 0.85 |
| Mar 31, 2023 | 0.84 |
| Dec 31, 2022 | 0.87 |
| Sep 30, 2022 | 0.84 |
| Jun 30, 2022 | 0.83 |
| Mar 31, 2022 | 0.74 |
| Dec 31, 2021 | 0.68 |
| Sep 30, 2021 | 0.66 |